345 related articles for article (PubMed ID: 20716336)
1. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
Moestue SA; Borgan E; Huuse EM; Lindholm EM; Sitter B; Børresen-Dale AL; Engebraaten O; Maelandsmo GM; Gribbestad IS
BMC Cancer; 2010 Aug; 10():433. PubMed ID: 20716336
[TBL] [Abstract][Full Text] [Related]
2. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
Grinde MT; Skrbo N; Moestue SA; Rødland EA; Borgan E; Kristian A; Sitter B; Bathen TF; Børresen-Dale AL; Mælandsmo GM; Engebraaten O; Sørlie T; Marangoni E; Gribbestad IS
Breast Cancer Res; 2014 Jan; 16(1):R5. PubMed ID: 24447408
[TBL] [Abstract][Full Text] [Related]
3. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.
Morse DL; Carroll D; Day S; Gray H; Sadarangani P; Murthi S; Job C; Baggett B; Raghunand N; Gillies RJ
NMR Biomed; 2009 Jan; 22(1):114-27. PubMed ID: 19016452
[TBL] [Abstract][Full Text] [Related]
4. In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.
Esmaeili M; Moestue SA; Hamans BC; Veltien A; Kristian A; Engebråten O; Maelandsmo GM; Gribbestad IS; Bathen TF; Heerschap A
J Magn Reson Imaging; 2015 Mar; 41(3):601-9. PubMed ID: 24532410
[TBL] [Abstract][Full Text] [Related]
5. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
Cao MD; Döpkens M; Krishnamachary B; Vesuna F; Gadiya MM; Lønning PE; Bhujwalla ZM; Gribbestad IS; Glunde K
NMR Biomed; 2012 Sep; 25(9):1033-42. PubMed ID: 22279038
[TBL] [Abstract][Full Text] [Related]
6. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
7. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
9. HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors.
Choi JS; Baek HM; Kim S; Kim MJ; Youk JH; Moon HJ; Kim EK; Han KH; Kim DH; Kim SI; Koo JS
PLoS One; 2012; 7(12):e51712. PubMed ID: 23272149
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
11. Expression of tight junction protein claudin-4 in basal-like breast carcinomas.
Kulka J; Szász AM; Németh Z; Madaras L; Schaff Z; Molnár IA; Tokés AM
Pathol Oncol Res; 2009 Mar; 15(1):59-64. PubMed ID: 18752049
[TBL] [Abstract][Full Text] [Related]
12. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
13. Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.
Esmaeili M; Bathen TF; Engebråten O; Mælandsmo GM; Gribbestad IS; Moestue SA
Magn Reson Med; 2014 Jun; 71(6):1973-81. PubMed ID: 23878023
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
17. Metabolic characterization of triple negative breast cancer.
Cao MD; Lamichhane S; Lundgren S; Bofin A; Fjøsne H; Giskeødegård GF; Bathen TF
BMC Cancer; 2014 Dec; 14():941. PubMed ID: 25495193
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Kreike B; van Kouwenhove M; Horlings H; Weigelt B; Peterse H; Bartelink H; van de Vijver MJ
Breast Cancer Res; 2007; 9(5):R65. PubMed ID: 17910759
[TBL] [Abstract][Full Text] [Related]
19. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
20. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
